# Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

> **NCT04266912** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Berzosertib

## Key facts

- **NCT ID:** NCT04266912
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-17
- **Primary completion:** 2024-11-13
- **Final completion:** 2025-12-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266912, "Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04266912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*